A montelukasztterápia betegterheinek változása a generikus árverseny hatására
作者： Balázs Répásy , Dóra Endrei , Antal Zemplényi , István Ágoston , Imre Boncz
关键词:
摘要: INTRODUCTION AND AIM The aim of our study was to analyse the public price montelukast sodium therapy in Hungary. METHOD Data derived from nationwide pharmaceutical database Hungarian National Health Insurance Fund Administration. We observed turnover and medicaments containing active substance 2007 2015. Accordingly, indicators were: consumer price, DCT (daily cost therapy), co-payment, quasi DOT (days treatment). RESULTS Due increasing DOT, total amount paid by patients increased until 2011, reaching 1 million USD; then, due generic competition blind bid methods, it decreased 490 000 USD. brand-name Singulair moved generics during 3 years (2011-2014). originator 10 mg tablets 1.1 USD 0.34 product Montelukast TEVA 0.67 0.16 period under review. CONCLUSION competition, patients' access drugs significantly: increased, co-payment decreased. Orv Hetil. 2018; 159(17): 682-687.
sci-hub.st 参考文章(13)
Imre Boncz, Tamás Evetovits, Csaba Dózsa, Andor Sebestyén, László Gulácsi, István Ágoston, Dóra Endrei, Tímea Csákvári, Thomas E. Getzen, The Hungarian Care Managing Organization Pilot Program. Value in health regional issues. ,vol. 7, pp. 27- 33 ,(2015) , 10.1016/J.VHRI.2015.04.005
Pieter Dylst, Steven Simoens, Does the Market Share of Generic Medicines Influence the Price Level? PharmacoEconomics. ,vol. 29, pp. 875- 882 ,(2011) , 10.2165/11585970-000000000-00000
Imre Boncz, Andor Sebestyén, Financial deficits in the health services of the UK and Hungary. The Lancet. ,vol. 368, pp. 917- 918 ,(2006) , 10.1016/S0140-6736(06)69369-0
Jaume Puig-Junoy, Impact of European pharmaceutical price regulation on generic price competition: a review. PharmacoEconomics. ,vol. 28, pp. 649- 663 ,(2010) , 10.2165/11535360-000000000-00000
Zoltán Kaló, József Bodrogi, Imre Boncz, Csaba Dózsa, Gabriella Jóna, Rita Kövi, Zsolt Pásztélyi, Balázs Sinkovits, Capacity Building for HTA Implementation in Middle-Income Countries: The Case of Hungary Value in health regional issues. ,vol. 2, pp. 264- 266 ,(2013) , 10.1016/J.VHRI.2013.06.002
Imre Boncz, Júlia Nagy, Andor Sebestyén, László Kőrösi, Financing of health care services in Hungary European Journal of Health Economics. ,vol. 5, pp. 252- 258 ,(2004) , 10.1007/S10198-004-0228-3
Dóra Endrei, Bálint Molics, István Ágoston, Multicriteria decision analysis in the reimbursement of new medical technologies: real-world experiences from Hungary. Value in Health. ,vol. 17, pp. 487- 489 ,(2014) , 10.1016/J.JVAL.2014.01.011
Ville Aalto-Setälä, The impact of generic substitution on price competition in Finland European Journal of Health Economics. ,vol. 9, pp. 185- 191 ,(2008) , 10.1007/S10198-007-0059-0
Dóra Endrei, Antal Zemplényi, Bálint Molics, István Ágoston, Imre Boncz, None, The effect of performance-volume limit on the DRG based acute care hospital financing in Hungary. Health Policy. ,vol. 115, pp. 152- 156 ,(2014) , 10.1016/J.HEALTHPOL.2013.12.005
László Gulácsi, Imre Boncz, Michael Drummond, Issues for countries considering introducing the "fourth hurdle": The case of Hungary International Journal of Technology Assessment in Health Care. ,vol. 20, pp. 337- 341 ,(2004) , 10.1017/S0266462304001151